Study Summary
This trial will help researchers understand how different levels of COVID-19 severity affect pulmonary function and how quickly patients recover.
- Coronavirus
Treatment Effectiveness
Phase-Based Effectiveness
Study Objectives
1 Primary · 0 Secondary · Reporting Duration: 6-months
Trial Safety
Phase-Based Safety
Awards & Highlights
Trial Design
1 Treatment Group
COVID-19 Survivors
1 of 1
Experimental Treatment
20 Total Participants · 1 Treatment Group
Primary Treatment: Hyperpolarized Xe129 · No Placebo Group · Phase 1
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 0 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
What additional investigations have explored the effects of Hyperpolarized Xe129?
"There are currently 15 Hyperpolarized Xe129 trials in progress, none of which are at their final stage. The majority of these experiments take place in Philadelphia but span across 21 medical locations." - Anonymous Online Contributor
Are healthcare professionals authorized to use Hyperpolarized Xe129 in treatment?
"Due to the limited amount of research data available, Hyperpolarized Xe129 has been given a safety rating of 1. As this is a Phase 1 trial, there is minimal evidence for efficacy and safety at present." - Anonymous Online Contributor
Are there any open slots left for participants in this research?
"Verified. Information hosted on clinicaltrials.gov confirms that this research endeavour, which was originally launched on February 22nd 2021, is currently recruiting individuals for participation. 20 persons need to be recruited from 1 medical centre." - Anonymous Online Contributor
How many participants are engaged in this trial?
"Affirmative. The records on clinicaltrials.gov verify that recruitment for this medical trial is still active since it was created in February 2021 and recently updated in August 2022. Currently, the research team needs to acquire 20 participants from a single facility." - Anonymous Online Contributor